Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Bydureon - labeled renal guidance
Product / population
Exenatide (Bydureon), extended-release powder and diluent for SC injection
All record notes are retained here, including notes about sources not selected in this review.
Bydureon - product and source limitations
This presentation has a 2024 FDA label. The 2018 FDA document for the product used different renal wording. Check the product presentation and label date.
What to reconcile: This presentation has a 2024 FDA label. The 2018 FDA document for the product used different renal wording. Check the product presentation and label date.
Use is not recommended below eGFR 45 or in end-stage renal disease. Monitor patients with mild impairment for effects that can cause hypovolemia. Verify the presentation and source date. In renal transplant recipients, monitor closely for adverse effects that deplete volume.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
